Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2018

View Archived Issues

Immix studies IMX-110 in patients with advanced solid tumors

Global BioLife completes Zaire Ebola research portion for study of LB-2

CXCR2 targeting suppresses allergic airway inflammation in mice

Magenta and Heidelberg Pharma sign exclusive multi-target research agreement

Zynerba plans pivotal study with ZYN-002 in fragile X syndrome

Vividion and Celgene enter strategic research collaboration

G1 Therapeutics reports phase IIa data on trilaciclib in extensive-stage SCLC

Promising topline data from pivotal phase III study of CLS-TA in uveitic macular edema

AEC syndrome pathology linked to protein aggregation of the p63 transcription factor

Phase III trials of olumacostat glasaretil for acne do not meet co-primary endpoints

FDA grants rare pediatric disease designation to Prometic's inter-alpha inhibitor proteins

Aminoacyclase-1 is a novel potential biomarker for schizophrenia

Enrollment begins in phase I study of treprostinil Technosphere

Safety, eosinophil reductions encourage further development of AK-002

Sorrento reports initial data from phase Ib study of autologous anti-CEA CAR T cells

Enteris signs feasibility development agreement with Ferring

Chi-Med initiates proof-of-concept study of epitinib in glioblastoma

Sanifit completes phase II trial of SNF-472 for calciphylaxis in patients on dialysis

Researchers mimic human walnut allergy in mice

Nightstar Therapeutics initiates phase III STAR trial of NSR-REP1 for choroideremia

Novel tubulin polymerization inhibitors discovered at Athenex

Merck & Co. patents new HCV NS5B inhibitors

Orbis Health Solutions presents anti-CTLA4 and PD-1-encoding bead vectors

Immatics Biotechnologies divulges novel constructs binding COL6A3 antigens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...